Exelixis, Inc. today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones..
KEYTRUDA doubled median DFS as adjuvant therapy versus observation – 29 months versus 14 months – in these patients
AMBASSADOR /KEYNOTE-123 is the first positive trial for KEYTRUDA as adjuvant.
Oncology trial shows positive results for patients with muscle-invasive urothelial carcinoma medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Alliance Study Shows Promising Results for Urothelial Carcinoma miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.